The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 12:14 PM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #76. PerkinElmer Shanghai Haoyuan Biotech Co., Ltd.,

Acquirer: PerkinElmer (NYSE:PKI)
Acquiree: Shanghai Haoyuan Biotech Co., Ltd.,
Details: PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced today that it has completed the acquisition of Shanghai Haoyuan Biotech Co., Ltd., a China-based infectious disease diagnostics company. The acquisition extends PerkinElmer's capabilities into nucleic acid blood screening and in the growing molecular clinical diagnostics market in China, further strengthening the Company's position as a diagnostics leader in China as well as across the globe.

PerkinElmer provides products, services and solutions for the diagnostics, life sciences and applied markets. Co. ‘s segments are: Discovery and Analytical Solutions and Diagnostics. Co.'s Discovery and Analytical Solutions segment serves: the life sciences, which consist of the life sciences research market and laboratory services market; and applied markets, which consist of environmental, food and industrial markets. Co.'s Diagnostics segment provides instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians and medical research personnel. Co.'s Diagnostics segment is focused on reproductive health, immunodiagnostics, diagnostics and applied genomics.

PerkinElmer SEC Filing Email Alerts Service


Open the PKI Page at The Online Investor »

Company Name: 
PerkinElmer, Inc.
Website: 
www.perkinelmer.com
Sector: 
Biotechnology
Number of ETFs Holding PKI: 
88
Total Market Value Held by ETFs: 
$2.68B
Total Market Capitalization: 
$17.94B
% of Market Cap. Held by ETFs: 
14.93%
 

Open the PKI Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PKI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.50 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
PKI Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 76 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.